Citizens National Bank Trust Department lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 68,122 shares of the company’s stock after acquiring an additional 2,250 shares during the quarter. Johnson & Johnson makes up 4.0% of Citizens National Bank Trust Department’s investment portfolio, making the stock its 2nd largest position. Citizens National Bank Trust Department’s holdings in Johnson & Johnson were worth $10,142,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Hussman Strategic Advisors Inc. bought a new position in Johnson & Johnson in the 3rd quarter worth about $1,519,000. Heritage Wealth Advisors raised its holdings in shares of Johnson & Johnson by 2.6% in the 3rd quarter. Heritage Wealth Advisors now owns 75,723 shares of the company’s stock valued at $11,274,000 after acquiring an additional 1,908 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of Johnson & Johnson by 379.7% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 46,929 shares of the company’s stock valued at $6,987,000 after acquiring an additional 37,146 shares in the last quarter. CWH Capital Management Inc. raised its holdings in shares of Johnson & Johnson by 2.5% in the 3rd quarter. CWH Capital Management Inc. now owns 18,694 shares of the company’s stock valued at $2,783,000 after acquiring an additional 459 shares in the last quarter. Finally, LFA Lugano Financial Advisors SA purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $228,000. Institutional investors own 67.44% of the company’s stock.
JNJ has been the topic of several recent analyst reports. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. Cantor Fitzgerald raised their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Finally, Credit Suisse Group raised their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $164.93.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.
Shares of JNJ stock opened at $146.36 on Friday. The firm has a market cap of $385.30 billion, a P/E ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The business’s 50 day moving average price is $145.51 and its 200-day moving average price is $146.57. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period last year, the company earned $2.12 EPS. As a group, equities analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: What is a dead cat bounce?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.